They will be reporting data on AB-506 in July. If the data is good and safe, ABUS can easily double from the current low valuation of only ~$1.50. There will be a lot of opportunities to license out AB-506 to companies like ALNY/VIR or DRNA. They may be interested in licensing that drug since they donít have capsid inhibitors for combination trial. I donít see anything wrong in licensing AB-506 to potential competitors since it will only expand the market opportunity for AB-506.